Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature by David A Barr & Pravistadevi K Ramdial
CASE REPORT Open Access
Clinicopathological correlates in HIV seropositive
tuberculosis cases presenting with jaundice after
initiating antiretroviral therapy with a structured
review of the literature
David A Barr1,2* and Pravistadevi K Ramdial3
Abstract
Background: The development of jaundice after initiation of HAART in HIV-TB co-infected patients is a challenging
presentation in resource constrained settings, and is often attributed to drug induced liver injury (DILI).Some
investigators have described hepatic tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) as a
cause of liver disease in patients initiating HAART, which could also cause jaundice.
Case presentations: We report the clinical and histopathological features of five HIV-TB co-infected patients
presenting with a syndrome of jaundice, tender hepatomegaly, bile canalicular enzyme rise and return of
constitutional symptoms within 8 weeks of initiation of highly active antiretroviral therapy (HAART) for advanced
HIV infection at a rural clinic in KwaZulu Natal, South Africa.
All five patients had been diagnosed with tuberculosis infection prior to HAART initiation and were on
antituberculous medication at time of developing jaundice. There was evidence of multiple aetiologies of liver
injury in all patients. However, based on clinical course and pathological findings, predominant hepatic injury was
thought to be drug induced in one case and hepatic tuberculosis associated immune reconstitution inflammatory
syndrome (TB-IRIS) in the other four.
In these later 4 patients, liver biopsy findings included necrotising and non-necrotising granulomatous
inflammation in the lobules and portal tracts. The granulomas demonstrated – in addition to epithelioid histiocytes
and Langhans giant cells – neutrophils, plasma cells and large numbers of lymphocytes, which are not features of a
conventional untreated tuberculous response.
Conclusion: In this high TB prevalent, low resource setting, TB-IRIS may be an important cause of jaundice
post-HAART initiation. Clinicopathological correlation is essential for optimal diagnosis. Further multi-organ based
histopathological studies in the context of immune reconstitution would be useful to clinicians in low resource
settings dealing with this challenging presentation.
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Background
The roll out of highly active anti-retroviral therapy
(HAART) is proceeding rapidly in low and middle in-
come countries, with the number of patients on anti-
retroviral therapy (ARV) rising from about one quarter
million at the end of 2002 to over five million at the end
of 2009 [1]. Anecdotally, the development of jaundice
after initiation HAART in HIV-TB co-infected patients
is more common in low resource, high tuberculosis
prevalent areas, and is often attributed to drug induced
liver injury (DILI).Some investigators have described
hepatic tuberculosis Immune Reconstitution Inflamma-
tory Syndrome (TB-IRIS) as a cause of liver disease in
patients initiating HAART, which could also cause jaun-
dice. However, the literature describing this presentation
is sparse. We describe five HIV seropositive tuberculosis
cases presenting with jaundice after initiating antiretroviral
therapy and consider DILI and TB-IRIS as aetiological fac-
tors and present detailed clinico-pathological description.
This is followed by a structured review of the literature
pertinent to these cases.
Background to cases
This article reports five patients presenting with jaun-
dice within two months of HAART initiation in rural
KwaZulu Natal, South Africa and discusses the possible
clinicopathological causes with a focus on tuberculosis-
associated immune reconstitution inflammatory syn-
drome (TB-IRIS) involving the liver. All five cases were
originally included in a prospective audit of HAART ini-
tiation in a rural district level ARV clinic in Nongoma,
KwaZulu Natal, South Africa. This audit recorded base-
line and follow-up data at 2 and 8 weeks post-HAART
initiation for 90 consecutive adult patients referred for
HAART initiation between 18th June and 27th July 2010.
The population that the cases are drawn from can there-
fore be accurately described from the audit sample
(Table 1).
Of the 90 patients in this audit series, six presented
with jaundice during 8 weeks of follow up post-HAART
initiation. Five of these six gave written consent to have
their cases reported and are presented below, the first
and fifth cases are described in detail while the
remaining three are summarised. All five patients under-




A 58 year old woman with a CD4 count of 23cells/μL
was referred for HAART initiation by a local general
practitioner. She had a 2 week history of fever, night
sweats, increasing dyspnoea and right sided chest pain,
in addition to 7 days of lethargy and fast palpitations.
She could walk only with assistance of 2 people. A large
right sided pleural effusion was detected, which was con-
firmed to be a lymphocytic exudate on cytological and
chemical testing. Apart from a mildly raised alkaline
phosphatase, liver function tests (LFTs) were normal,
and hepatitis B surface antigen was negative. She was ad-
mitted for inpatient care and commenced on empirical
quadruple anti-tubercular therapy as per South African
national guidelines [2] (rifampicin, isoniazid, pyrazina-
mide and ethambutol), along with a 5 day course of cef-
triaxone and prophylactic co-trimoxazole. In addition 4
litres of fluid was drained from the pleural space.
Induced sputum and pleural fluid were acid fast bacilli
(AFB) negative.
After two weeks, the fever, night sweats, chest pain
and palpitations had resolved. She could walk unaided.
A small pleural effusion and mild abdominal tenderness
in the right upper quadrant remained, but there was no
hepatomegaly. She was commenced on efavirenz, teno-
fovir and lamivudine as per national guidelines [3].
At routine review two weeks post-HAART initiation
she was found to be confused with fever, dyspnoea, and
chest pain. She had again lost her ability to walk un-
aided. Examination revealed jaundice, a re-accumulated
pleural effusion and new tender hepatomegaly. Ultra-
sound scan of the abdomen identified epigastric lymph
nodes >3 cm in diameter and an enlarged liver with ab-
normal texture. The LFTs demonstrated marked eleva-
tion in bile canalicular hepatic enzymes; raised bilirubin
was predominantly conjugated, and clotting studies were
normal (Table 3). A liver biopsy was performed which
showed necrotising (Figure 1A, 1B) and non-necrotising
(Figure 2A) granulomatous inflammation with AFB.
Some of the necrotising granulomas demonstrated
caseative necrosis (Figure 1A) while others were
Table 1 Baseline characteristics of patient population
case series is drawn from
Baseline characteristic Value
Median age in years (IQR) 34 (29 to 40)
Median CD4 cells/μL (IQR) 135 (70 to 194)
%female 67%
% with cultured confirmed TB as
part of HAART initiation work up
~40%
% diagnosed with TB as part of
HAART initiation work up
~50%
% with alanine transaminase
elevation grade≥ 1
28%
% with alanine transaminase
elevation grade≥ 3
3%
% with alkaline phospatase > 98U/L
(female) or > 128U/L (male) at
time of HAART initiation
43%
IQR = Inter-quartile range.
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suppurative (Figure 1B). All the granulomas also con-
tained a lymphocytic infiltrate with an admixed CD3+/
CD4+ and CD3+/CD8+immunoprofile. The latter predo-
minated (Figure 2B). There was also cholestasis and a
mixed, predominantly macrovesicular,steatosis, and no
viral inclusions (Table 2). Pleural fluid and mycobacter-
ial blood culture sent at the time of first presentation
confirmed fully sensitive Mycobacterium tuberculosis.
The jaundice was felt to be primarily due to hepatic
TB IRIS. HAART and TB therapy were continued, and a
14 day course of prednisolone 30 mg OD prescribed. All
symptoms resolved over a 4 week period, along with the
normalisation of observation chart variables, resolution
of the hepatomegaly and pleural effusion.
Patients 2, 3 and 4
The clinical and laboratory features of patients 2, 3
and 4 were similar to patient 1, and are summarised
below. TB-IRIS was favoured as a primary cause of
jaundice in these three cases. The histopathological
features of patients 2 and 3 were also similar to
patient 1. The biopsy from patient 4 was inadequate
for optimal appraisal and investigation; this patient’s
working diagnosis was based on clinical and non-
biopsy laboratory findings.
Patient 2 was a 33 year old man with a history of prob-
lem alcohol use and pleural TB treated the previous
year. He had a CD4 count of 61 cells/μL and had repeat
treatment for pleural and pericardial TB starting three
weeks prior to HAART initiation. After four weeks of
HAART he deteriorated with re-accumulated effusions,
plus new jaundice and tender hepatomegaly. Liver
enzymes were cholestatic and abdominal ultrasound
showed diffusely abnormal liver with epigastric lymph-
adenopathy. He was thought to have underlying chronic
liver disease secondary to hepatitis B virus and alcohol
consumption, with a superadded hepatic TB-IRIS, and
was successfully managed with continued HAART and
TB drugs with inpatient monitoring of liver enzymes.
Patient 3 was a 38 year old female diagnosed com-
menced on pulmonary TB therapy 2 weeks prior to
HAART initiation (CD4 32 cells/μL). She then did not
Table 2 Summary of histopathological findings
Feature Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Hepatocytes
Swelling mild marked mild mild marked
Regeneration Present Present Present Present Present
Steatosis Patchy Diffuse Patchy Patchy Diffuse
Cholestasis Present Present Present Present Present
Inflammation
NGI Portal/parenchymal Portal/parenchymal Portal/parenchymal Absent Absent
NNGI Portal/parenchymal Portal/parenchymal Portal/parenchymal Absent Absent
Langhans GC NGI/NNGI NGI/NNGI NGI/NNGI Absent Absent











T dominant (dominant CD8+)
PCs Portal Portal Portal & parenchymal nil Portal & parenchymal
EPs Portal/parenchymal Portal/parenchymal Portal/parenchymal nil *Portal/parenchymal
HCs Portal/parenchymal Portal/parenchymal Portal/parenchymal nil Portal/parenchymal
Other
Architecture Maintained Mixed cirrhosis Maintained Cannot comment Maintained
Fibrosis Portal Fibrous linkages Portal Cannot comment nil
I/hepatitis Absent Absent Absent Cannot comment Present
ZN Paucibacillary Negative Negative Not done- no tissue Negative
PCR Positive Positive Positive Not done – no tissue Negative
Haemosiderin Present Present Present Present Present
Key: EPs: presence and dominant location of eosinophils; HC: presence and dominant location of histiocytes; I/hepatitis: interface hepatitis; Langhans GC: presence
and location of Langhans giant cells; LCs: presence, dominant location & subtype of lymphocytes; NNGI: presence and location of non-necrotising granulomatous
inflammation; NGI: presence and location of necrotising granulomatous inflammation; NPs: presence and dominant location of neutrophils; PCs presence and
dominant location of eosinophils; PCR polymerase chain reaction; ZN ZiehlNeelsen stain.
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attend for follow up for 6 weeks, when she had deterio-
rated with systemic symptoms and functional decline,
plus a worsened chest x-ray. Jaundice and tender he-
patomegaly were noted, with cholestatic pattern liver
enzymes. Disseminated TB-IRIS was suspected (includ-
ing hepatic); TB therapy and HAART were continued
but prednisolone not given as sensitivity results from
mycobacterial culture were still pending. She made a full
recovery.
Patient 4 was a 41 year old man with CD4 123 cells/
μL who had a prolonged hospital admission during
which he was treated for disseminated tuberculosis in-
fection, being commenced on HAART on discharge
(after 4 weeks TB therapy). At two week review he was
Table 3 Chronological selected blood indices for patient 1 and 5
Week since starting HAART Alb Total Bil ALT ALP GGT Hb WCC plt lactate INR
Patient 1
−2 First visit to ARV clinic 23 5 13 152 73 7.4 6.5 394 n/a
0 26 11 20 131 89 8.0 5.5 314 n/a
+2 Presents with jaundice 2 weeks
post HAART
20 88* 127 833 429 7.0 3.1 803 2.9 1.3
+4 Starts 14 days prednisolone 17 62 99 1310 673 7.0 2.9 736 n/a 1.0
+8 Clinically improved 24 22 49 667 330 7.9 3.9 448 n/a 1.0
Patient 5
−2 First visit to ARV clinic 22 18 34 119 35 11.3 5.4 364 n/a n/a
0 After 2 weeks TB treatment starts HAART 24 21 45 133 57 9.3 4.4 682 n/a n/a
+2 Has been found to have jaundice 10 days
post HAART; TB treatment stopped
21 56* 60 115 99 n/a n/a n/a 2.7 1.3
+3 With resolving jaundice and clinical
deterioration TB treatment restarted
26 26 48 138 93 9.5 2.6 460 2.6 1.2
+4 Return of jaundice and liver biopsy suggests
DILI – TB treatment stopped
21 97 67 187 148 9.2 2.7 424 1.6 1.4
* > 85% conjugated bilirubin.
Alb albumin in g/L, Bil total total bilirubin μmol/L, ALT alanine aminotransteraseiu/L, ALP alkaline phosphatase iu/L, GGT Gamma-glutamyltranspeptidaseiu/L., Hb
haemoglobin in g/dL; WCC = white cell count (total) x109/L; plt = platelets x109/L; lactate is measured in mmol/L; INR = international normalised ratio.
Figure 1 (Patient 1) Necrotising granulomatous inflammation
(g) with mixed inflammatory cells and caseative necrosis
(A, asterisk) and suppurative inflammation (B, asterisk)
[haematoxylin & eosin].
Figure 2 (Patient 1) Lobular non-necrotising granulomatous
inflammation (A) with central aggregation of epithelioid
histiocytes (asterisk) (h = hepatocytes) [hematoxylin & eosin],
and prominent CD8+ T-lymphocytic infiltrate (B).
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unwell with systemic symptoms, jaundice, new hepato-
splenomegaly, epigastric lymphadenopathy and a dete-
riorated chest x-ray. Although ALT was significantly
raised (grade 3) liver enzyme derangement was mixed,
predominantly cholestatic. A fully sensitive Mycobacte-
rium tuberculosis was grown from his induced sputum
and he was treated for multi-systemic (and hepatic) TB-
IRIS with prednisolone and made a rapid recovery.
Additional clinical details on cases 2,3 and 4 are avail-
able in Additional file 1: Table S1.
Patient 5
A 34 year old woman with CD4 count 17 cells/μL was
referred from a local hospital outpatient department for
initiation of HAART. However, she reported 2 months
intermittent diarrhoea which was watery with associated
abdominal cramp pain, and vomiting after food. There
was also a 2 month history of lethargy, anorexia, and
weight loss. On direct questioning she also described a
dry cough for the last 4 days. She had been diagnosed
previously with tuberculosis, and finished treatment
4 months prior to this presentation.
Examination findings included cachexia, tachycardia,
temperature of 37.7°C, oral candidiasis and a long
standing hyperpigmented rash of prior pruritic papular
eruption. Abdominal palpation revealed a tender epi-
gastric fullness and possible mass or medial liver en-
largement. Chest radiology demonstrated calcified hilar
nodes and a sub-pulmonic effusion while ultrasound
scanning confirmed pleural fluid and epigastric lymph-
nodes greater than 3 cm and hepatomegaly of normal
texture. Routine blood biochemistry and full blood
count results included mild hyponatraemia, normocytic
anaemia, and hypoalbuminaemia. Induced sputum was
sent for mycobacterial culture, and stool and blood
were sent for bacterial culture, but the pleural effusion
was too small for aspiration. She was commenced on
quadruple therapy for tuberculosis plus streptomycin
as a ‘re-treatment’ case of pleural tuberculosis as per
the national South African guidelines. Prophylactic
dose co-trimoxazole was also initiated.
Two weeks later the pyrexia had resolved, but the diar-
rhoea and tachycardia persisted and she had a postural
drop in blood pressure. Admission for intravenous fluids
and antibiotics for gastroenteritis (ceftriaxone, erythro-
mycin) was arranged and HAART was initiated (efava-
renz, lamivudine and tenofovir as per national guidelines).
Previous aerobic blood cultures and stool culture showed
no growth.
The vomiting and diarrhoea had resolved 10 days into
admission but the patient was noted to have jaundice,
high fever, on-going tachycardia and weight loss. On
examination there was now a 4 finger width tender he-
patomegaly and a moderate sized right sided pleural
effusion. The ward doctor discontinued tuberculosis
treatment and continued co-trimoxazole and HAART.
Over the next 7 days there was continued fever and
weight loss, with some resolution of abnormal liver func-
tion tests (Table 3). Aspirate of the pleural effusion con-
firmed a lymphocytic exudate. Ultrasound imaging
showed an enlarged liver, normal biliary tree, normal
spleen, no large nodes, and no free fluid; a liver biopsy
was performed.
After a 10 day interruption, because of improved liver
biochemistry and progressing clinical deterioration felt
to be due to disseminated tuberculosis, full TB treat-
ment was restarted. This again resulted in worsening
liver biochemistry (Table 3). The liver biopsy (Table 2)
(Figure 3) demonstrated necroinflammatory foci with
eosinophils, marked hepatocyte swelling, regenerative
activity with multinucleation and diffuse mixed macro-
and-microvesicularsteatosis and cholestasis. The portal
tracts were expanded by a mixed, but predominantly
lymphoplasmacytic and eosinophilic, infiltrate. There
was irregularity of the portal-parenchymal interface in 2
portal tracts with conspicuous destruction of hepato-
cytes by lymphocytes in these foci. Granulomas were not
identified. Mycobacterial PCR investigation was negative.
Tuberculosis therapy was stopped for a second time
with a plan to reintroduce at a later date using a drug
hepatotoxicity protocol. However, all mycobacterial cul-
ture results (induced sputum and pleural fluid) were
negative at 42 days, the patient’s symptoms resolved and
she gained weight. It was felt her jaundice was primarily
drug induced liver injury, although cholestasis relating
to bacterial sepsis is also a possibility. The lymphocytic
pleural exudate and abdominal lymphadenopathy may
have been a paradoxical reaction to residual TB antigen
Figure 3 (Patient 5) Dense, predominantly lymphoplasmacytic,
portal (P) inflammatory infiltrate with scattered eosinophils and
lobular necroinflammatory foci (L, arrow) with apoptotic
hepatocytes (arrow) [hematoxylin & eosin].
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from her previously treated tuberculosis. She remained
well without TB treatment at 12 months follow up.
Discussion
All five patients discussed above had a diagnosis of tu-
berculosis made pre-HAART and were on TB therapy at
time of HAART initiation. They were immunosup-
pressed, as evidenced by clinical findings and CD4
count. All presented with new tender hepatomegaly,
jaundice with bile canalicular enzyme rise and preserved
liver synthetic function, as evidenced by normal clotting
studies and return of constitutional symptoms within
8 weeks of initiation of HAART. Ultrasound scan was
not diagnostic in any of the patients; in particular none
had bile duct dilatation. There was evidence of multiple
potential aetiologies in all patients, but the predominant
cause was felt to be DILI in one case and hepatic TB-
IRIS in the other four. We discuss these findings in the
context of previous literature under the headings liver
disease in HIV infection, drug induced liver injury and
hepatic TB IRIS below.
Liver disease in HIV infection
In the pre-HAART era abnormal liver enzymes were
regarded common in HIV, with prevalence rising with
advancing immunosuppression [4,5]. Histopathology
studies demonstrated a multiplicity of HIV associated
disease in the liver, with aetiology differing widely in
different population settings [6-10]. Despite this, jaun-
dice has been regarded as infrequent in HIV [11].
Again, as might be expected, the incidence and aeti-
ology of jaundice in HIV-infected patients may vary in
different populations [12,13].
Since the introduction of HAART there has under-
standably been greater focus on drug associated hepato-
toxicity in HIV. In high income settings, chronic liver
disease – associated with Hepatitis C and B virus, long
term drug-induced toxicity, alcohol related and non-
alcoholic fatty liver disease – has become a leading cause
of chronic morbidity and mortality in people living with
HIV [14]. Mechanisms underlying long-term hepatic in-
jury are probably distinct from hepatotoxicity seen
acutely after introduction of HAART [15]. Early severe
hepatotoxicity (SH) is often arbitrarily defined as ele-
vated serum aminotransferases >5 times the upper limit
of normal (grade 3 and above by the AIDS Clinical Trial
Group classification) within the first 6 months of
HAART; in randomised controlled trials (RCTs) inci-
dence of SH ranges from 2 to 18% [16], and may have
even greater variability in observational studies [17].
However there are well described problems with asses-
sing hepatotoxicity of HAART in randomised and obser-
vational trials [18]. Asymptomatic elevations in liver
enzymes may not be an accurate surrogate for risk of
developing rare, clinically relevant, liver disease. Further-
more, the biochemical definition of hepatotoxicity is not
standardised despite use of the AIDS Clinical trial Group
(ACTG) classification. Although ACTG give parameters
for significant elevation of all liver enzymes [19], many
studies only include transaminase elevations – raised
total bilirubin is often inconsistently defined, and alka-
line phosphatase rarely considered. Which liver enzymes
are included can have a large effect on conclusions [20].
In addition, when considering patients with baseline ab-
normalities of transaminases investigators generally use
modified ACTG criteria (for example elevations of trans-
aminases > 3.5 times baseline), but such modifications
are not standardised. Finally, upsets in liver enzymes can
occur in the absence of HAART, but in hepatotoxicity
studies all significant hepatic abnormalities are attribu-
ted to “toxicity”, or it is often not clear how investigators
have excluded cases due to other causes.
Nevertheless, it is clear that, again, in high income set-
tings co-infection with viral hepatitides is pivotal in de-
termining risk of early hepatotoxicity [21-24]. By
comparison, HIV cohorts in limited resource settings
tend to have much lower rates of Hepatitis C infection,
and are more likely to use nevirapine in first line regi-
mens. Hepatotoxicity studies in these settings reveal a
heterogeneous picture. Reported rates of early hepatotox-
icity in people initiating HAART in African studies are
generally low at 1-2% [25-33] but occasionally much
higher at 3.4-18.4% [34-37]. Grade 1 or 2 rises in liver
enzymes are very prevalent in all these studies. Some well
conducted studies have reported a significantly higher
rate of early grade 3 or 4 hepatotoxicity in patients trea-
ted with nevirapine compared to efavarenz [25,37], while
other studies have not [26]. Co-infection with viral hepa-
titides is not found to be a significant risk factor for hep-
atotoxicity [25,26,28,34,37], in most but not all studies
[35]. In contrast, co-treatment with anti-tuberculous
medications is found to be a major risk factor in African
cohorts [25,28,35], although this also has exceptions [29].
Different follow up times and frequencies of serum
liver enzyme assessment may explain much of this
variation – for example the studies which have found
high rates of early nevirapine associated hepatotoxicity
have higher rates of blood sampling in the first 3 months
post-HAART initiation, which is when most hepatoto-
xicity was identified, suggesting other studies may simply
have missed this occurrence.
In correspondence with the high income setting stu-
dies, there is also the problem of definition of hepato-
toxicity. This difficulty is underlined in light of the
finding that point prevalence of ‘grade 3 or 4 hepatoto-
xicity’ may be very similar before and after HAART initi-
ation [35], or that HAART initiation even reduces the
rates of transaminitis in African HIV treatment cohorts
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[28]. This suggests trials which define HAART related
hepatotoxicity as any significant rise in liver enzymes
after HAART initiation have oversimplified a complex,
multifactorial problem.
Helping get beyond these problems are papers that re-
port clinically relevant outcomes, which several studies
in an African setting do. Reported rate of changing
HAART regimen in response to hepatotoxicity is gene -
rally lower than reported rate of grade 3 or 4 liver en-
zyme rise – for example 0.7% v. 1.4%; [30] 9.1% v. 13.8%;
[37]; 2.6% v. 3.4%; [36] 0.9% v. 4.6% [35]. It is possible
that clinicians do not always think such rises are herald-
ing life threatening drug induced liver injury, perhaps
relying instead on additional features such as lactic acid-
osis, hypersensitivity rash or eosinophilia or are reassured
by the transient nature of a rise. Several investigators have
recorded that grade 3 or 4 liver enzyme abnormalities
often resolve spontaneously without change in medica-
tions [29,37]. However, some investigators have noted
higher incidence of symptoms in those with compared to
those without grade 3 or 4 liver enzyme elevation [35,37].
Importantly, while deaths attributed to HAART hepato-
toxicity are infrequent, they do occur; reported rates are 0
to 0.5% [35-37].
Further clinical context is provided in some hepatoto-
xicity studies. In reports of hepatotoxicity in a treatment
cohort in rural Uganda [28,38], Weidle and colleagues
describe clinical hepatitis – defined as presence of jaun-
dice, liver enlargement and gastrointestinal symptoms –
in 4 out of 1029 enrolled patients within 3 months of
HAART initiation. Although 12.7% of this cohort
received TB treatment, none of the 4 patients with cli-
nical hepatitis were on anti-mycobacterial medication at
the time of their reactions. All 4 patients also exhibited a
hypersensitivity rash, one case was caused by co-trimoxazole,
and 3 were attributed to nevirapine; one of the 4 patients
died from the reaction.
Kalyesubula et al. reporting from urban clinics in
Kampala give a detailed account of clinical and bioche-
mical surveillance for hepatitis in HIV seropositive
patients [25]. In a cohort of 236 individuals, 66 deve-
loped new transaminitis within 14 weeks of commencing
HAART, although only 3/66 were grade 3 or 4 rises. The
investigators report that, in the 66 patients with any
aminotransferase elevation, 33% had vomiting, 20% right
upper quadrant pain, 17% hepatomegaly and 8% jaun-
dice. Although only 8/236 patients were receiving any
TB treatment, the authors found current TB therapy to
be a risk factor for any grade 2 – 4 transaminitis, but it
is not clear what clinical findings were observed in HIV-
TB co-infected patients who developed transaminitis.
Unlike in this previous work, the current case series is
defined by a clinical presentation rather than the pre-
sence or absence liver enzyme elevation. In addition, we
present a detailed clinico-pathological description in an
attempt to better define the causes of the liver disease in
these patients, which is not found in the literature on
hepatotoxicity post-HAART. It should be emphasised
that the treatment cohort these cases are drawn from
may be quite atypical compared to some of the above
studies. In particular, the very high rate of culture con-
firmed tuberculosis in our cohort (about 40% from sam-
ples obtained during HAART initiation work up).
Drug Induced Liver Injury (DILI)
There is no gold standard for the diagnosis of DILI.
The clinical and histopathological spectrum of DILI is
wide and overlaps with other hepatic diseases. The more
common hepatitic pattern of DILI, with ALT >5 times
upper limit of normal, was not apparent in these five
patients who had predominant bile canalicular enzyme
elevation. However, cholestatic or mixed hepatocellular/
cholestatic DILI has been reported with use of rifampicin,
[39] isoniazid [40], ethambutol [41], and co-trimoxazole
[42], hence, drug hepatotoxicity must still be considered.
In lieu of a gold standard diagnostic test, clinical scales
for diagnosis of DILI have been developed. One of the
most validated is the Maria &Victorino (M&V) system
[43]. Based on the M&V system score, patient 5 above
might be considered a ‘possible’ DILI, while patients 1 to
4 score as ‘unlikely’ to be DILI. Caution must be taken in
application of DILI clinical scales: poor reproducibility
along with inter-rater and inter-scale disagreement have
been shown [44], and they are not validated in HIV- posi-
tive populations or low resource settings. Despite these
limitations, from a clinical perspective, worsening of
LFTs on drug re-challenge in patient 5 is strong evidence
of DILI, and normalisation of LFTs without interrupting
therapy is strong evidence that DILI was not a predomi-
nant cause of the jaundice seen in the four other cases.
Histopathologic assessment of possible DILI can also
be problematic. Drug hepatotoxicity can produce a
spectrum of acute hepatic pathology that imitates a
range of patterns described in primary hepatic disease
[45,46]. This mimicry poses a major diagnostic challenge
because the shared histopathological features, compri-
sing mainly necro-inflammatory hepatocellular, chole-
static and mixed hepatocellular-cholestatic patterns,
cannot be attributed unequivocally to drugs [45,47]. Al-
though this wide spectrum of histopathological reaction
patterns displayed in DILI includes a granulomatous re-
action pattern, drug-induced granulomatous responses
are usually non-necrotising. Because 3/5 patients in the
present study demonstrated necrotizing granulomatous
inflammation, a drug-induced cause is morphologically
inappropriate. This is also strengthened by the identifi-
cation of acid fast bacilli in one biopsy and confirmation
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of an M. tuberculosis complex footprint by polymerase
chain reaction.
One of the five biopsy results in these cases was con-
sidered strongly suggestive of DILI and resulted in deci-
sion to interrupt TB medications (case 5, Figure 3,
histology showed moderate portal tract and lobular in-
flammation with eosinophils and interface hepatitis). The
presence of eosinophils is a well-recognised feature of
drug reactions in many organs, but caution is necessary
in the interpretation of their presence. This is particularly
pertinent in the current context, because patients with
advanced AIDS demonstrate a dominant Th2 response
with associated tissue “eosinophilia”. Furthermore, silent
parasitic infections may be responsible for heightened
eosinophil numbers. Notwithstanding this, however,
whilst all biopsies in the present study contained eosino-
phils, the density of eosinophils was most intense in the
biopsy from patient 5. In this biopsy, there were no other
histopathological clues of a parasitic infestation.
In summary, no gold-standard exists for diagnosis of
DILI, but liver biopsy with clinicopathological corre-
lation suggests DILI as a probable primary cause of he-
patic disease in only one of the five cases presented here.
Hepatic TB-IRIS
Although tuberculosis of the liver is not commonly diag-
nosed clinically, it is a frequent post-mortem finding in
HIV positive patients [48]. It is possible that hepatic tu-
berculosis (IRIS) may be similarly under recognised.
Lawn and Wood [49] report not infrequent involvement
of the liver in South African patients with TB-IRIS –
four patients in a case series of seventeen TB-IRIS
patients. They suggest that predominant rise in bile
canalicular enzymes, liver capsular pain, manifestations
of TB-IRIS at another anatomical site, are all suggestive
features, while jaundice may develop in some patients.
Meintjes et al. [50] have also shown high prevalence of
cholestatic pattern liver enzyme derangement and he-
patomegaly in South African patients diagnosed with
TB-IRIS in a large prospective observational study, but do
not comment specifically on jaundice. Similarly, Haddow
et al. [51] report a high frequency of elevated liver
enzymes in a cohort of South African patients initiating
HAART who were consequently classified as possible
cases of hepatic TB-IRIS by expert consensus. By contrast
other TB-IRIS cohort studies do not report any liver in-
volvement [52]. Such variability may represent differences
in study populations or may relate to diagnostic difficulty.
In likeness with DILI, TB-IRIS has no diagnostic gold
standard test, but a consensus clinical case definition has
been proposed for low income settings [53]. Four of the
five jaundiced patients in this series were felt to have met
this TB-IRIS case definition (Additional file 1: Table S2).
A specific case definition for hepatic TB-IRIS has also
been suggested, which additionally requires the presence
of granulomatous inflammation on liver biopsy [50].
Lawn and Wood suggest that large epithelioid granu-
lomatous inflammation seen on liver biopsy is evidence
of hepatic TB-IRIS [49]. In the present study, not only
was necrotising and non-necrotising granulomatous in-
flammation present in the lobules and portal tracts, but
the granulomas demonstrated – in addition to epithe-
lioid histiocytes and Langhans giant cells – neutrophils,
plasma cells and large numbers of lymphocytes, which
are not features of a conventional untreated tuberculous
response. The microscopic spectrum of the tuberculous
IRIS reaction is poorly documented, but a similar dense
neutrophilic and lymphoplasmacytic inflammatory re-
sponse has been documented in reaction to cryptococcal
antigen in tissue [54]. Although the present study is li-
mited by the absence of interval CD4 counts and viral
load measurements, in view of the other laboratory find-
ings and clinical history, including patient outcome, the
spectrum of histopathological findings is proposed as
the expanding morphological profile of tuberculous
granulomas in the setting of IRIS. We believe this is the
most detailed clinico-pathological description of hepatic
TB-IRIS to date. Further multi-organ based histopatho-
logical studies in multiple organs are necessary for such
validation.
Multiple causes of jaundice in individual patient
Immune-compromised patients are often found to have
multiple concurrent liver pathologies [55]. The majority
of cases presented above have evidence of more than
one potential cause of jaundice. A further contributor to
jaundice in these cases could be the isolated hyperbiliru-
binaemia (without evidence of cholestasis or hepatocel-
lular damage) related to rifampicin interference with
bilirubin uptake [56-58]. Heller et al. [59] postulate this
may be at least a partial cause of their ‘relatively fre-
quent’ observation of jaundice shortly after initiation of
TB medications in South African patients. This might be
particularly relevant to patient 5 in this case series, who
had jaundice in the presence of only minor alkaline
phosphatase elevation.
Preliminary guidelines on how healthcare workers in
resource-limited settings should respond to jaundice in
HIV positive TB cases on antiretroviral therapy
A lack of evidence exists informing the management of
the clinical presentation of jaundice in this context and
the preliminary nature of the following guidance should
be emphasised.
 Presentation with jaundice in HIV positive patients
on TB treatment and HAART should prompt full
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clinical assessment. Bloods for biochemical and
haematology assays, and ultrasound assessment of
the abdomen should be performed if available.
 Elevations in transaminases or bilirubin >5x upper
limit of normal, or >3.5x the baseline level, are not
typical of hepatic TB-IRIS. If present, clinicians
should strongly suspect DILI and follow local or
national guidelines for hepatotoxicity from anti-
tuberculosis and anti-retroviral medications.
 The presence of hypersensitivity rash, lactic acidosis,
significant coagulopathy or eosinophilia is strongly
suggestive of DILI and clinicians should follow local
or national guidelines for hepatotoxicity from anti-
tuberculosis and anti-retroviral medications.
 In cases where anti-tuberculosis and/or anti-
retroviral medications have been discontinued but
liver enzymes are failing to resolve, liver biopsy
should be considered if available.
 Features suggestive of hepatic TB-IRIS as a cause of
jaundice include:
 evidence of IRIS in another system;
 new tender hepatomegaly;
 predominantly cholestatic liver test derangement;
 abdominal ultrasound findings of diffusely
abnormal liver texture, lymphadenopathy and
normal biliary tree.
 If diagnostic uncertainty exists clinicians should
consider liver biopsy, if available, or transfer to a
higher level of care.
 Histopathological findings which suggest TB-IRIS in
liver tissue include large epithelioid granulomatous
inflammation. Features which are atypical of
conventional tuberculous response – including
neutrophils, plasma cells and large numbers of
lymphocytes – may also be present.
 Multiple causes of liver disease are common in
HIV-TB co-infected patients presenting with
jaundice following HAART initiation, and additional
diagnoses such as bacterial sepsis, DILI from
traditional medicines, and active hepatitis B
infection should be actively sought.
 Causes of liver disease in HIV-TB co-infected
patients show wide variation in relative frequency
according to geographical location and population
studied; clinicians should be aware of local and
national experience for their setting.
Conclusion
HIV seropositive tuberculosis cases presenting with
jaundice after initiating antiretroviral therapy represent a
challenge to clinicians working in resource constrained
settings. We believe hepatic TB-IRIS is an important
aetiological factor in our setting. Fastidious clinicopatho-
logical correlation is essential for optimal diagnosis. Pro-
spective histopathological studies in multiple organs for
better characterisation of the morphological profile of
tuberculous granulomas in the setting of immune recon-
stitution are necessary to aid clinical decision making in
difficult cases such as those presented here.
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